This Web Site contains forward-looking statements or information (collectively “forward-looking statements”) that are based on Canivate’s current expectations, estimates, forecasts, projections, beliefs and assumptions made by Canivate’s management about the industry in which Canivate operates. Such statements include, in particular, statements about our plans, strategies and prospects. These statements are not guarantees of future performance and involve assumptions and risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Canivate does not intend, and disclaims any obligation, to update any forward-looking statements that it has included in our Web Site, whether as a result of new information, future events or otherwise, except as required law. Canivate is at the early stages of developing its business and its ability to achieve its business plans are subject to considerable risks, uncertainties and other factors and accordingly there is no assurance that Canivate will be successful in executing on its business strategies.  The risks, uncertainties and other factors, many of which are beyond the control of the Company that could influence actual results include, but are not limited to:
  • the Company is a development stage company with little operating history, a history of losses and the Company cannot assure profitability;
  • the Company has not constructed any Canivate micropropagation laboratories or cultivation facilities to date and costs of construction and operating may be greater than anticipated, and the laboratories and facilities may not achieve the anticipated production or operational results
  • uncertainty about the Company’s ability to continue as a going concern;
  • the Company has negative cash flow for the year ended December 31, 2018 and the three-month period ended March 31, 2019;
  • the Company’s actual financial position and results of operations may differ materially from the expectations of management;
  • the Company expects to incur significant ongoing costs and obligations relating to its investment in infrastructure, growth, regulatory compliance and operations;
  • there are factors which may prevent the Company from the realization of growth targets;
  • the Company is subject to changes in Canadian laws, regulations and guidelines, which could adversely affect the Company’s future business, financial condition and results of operations;
  • there is no assurance that the Company will turn a profit or generate revenues;
  • the Company may not be able to effectively manage its growth and operations, which could materially and adversely affect its business;
  • the Company may be unable to adequately protect its proprietary and intellectual property rights;
  • the Company may be forced to litigate to defend its intellectual property rights, or to defend against claims by third parties against the Company relating to intellectual property rights;
  • the Company may become subject to litigation, which may have a material adverse effect on the Company’s reputation, business, results from operations and financial condition;
  • the Company faces competition from other companies where it will conduct business that may have a higher capitalization, more experienced management or may be more mature as a business;
  • if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis and hemp market;
  • there is no assurance that the Company will obtain and retain any relevant licenses;
  • the size of the Company’s target market is difficult to quantify and investors will be reliant on their own estimates on the accuracy of market data;
  • the Company’s industry is experiencing rapid growth and consolidation that may cause the Company to lose key relationships and intensify competition;
  • the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders;
  • the Company currently has insurance coverage; however, because the Company’s business is ancillary to the cannabis industry, there are additional difficulties and complexities associated with such insurance coverage;
  • the Company does not anticipate the ability to immediately diversify its business;
  • the Company may face significant competition from other facilities;
  • the Company could be liable for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses to claims against the Company;
  • the Company will be reliant on information technology systems and may be subject to damaging cyberattacks;
  • the Company may be subject to breaches of security at its facilities, or in respect of electronic documents and data storage, and may face risks related to breaches of applicable privacy laws;
  • the Company’s officers and directors may be engaged in a range of business activities resulting in conflicts of interest;
  • in certain circumstances, the Company’s reputation could be damaged;
  • the Company is operating at a regulatory frontier. The cannabis and hemp industries are new industries that may not succeed and, as a result of the Company’s ancillary involvement in such industry, the Company’s business may suffer;
  • the Company may not be able to obtain all necessary licenses and permits or complete construction of its facilities in a timely manner, which could, among other things, delay or prevent the Company from becoming profitable;
  • regulatory scrutiny of the Company’s industry may negatively impact its ability to raise additional capital;
  • some of the Company’s planned business activities, while believed to be compliant with applicable certain U.S. state and local law, are illegal under United States federal law;
  • the enforcement of relevant laws is a significant risk;
  • the Company’s investments and operations in the United States may be subject to heightened scrutiny;
  • the Company’s directors, officers, employees and its investors may face challenges entering the United States;
  • the Company may have difficulty accessing the service of banks and processing credit card payments in the future, which may make it difficult for the Company to operate;
  • due to the classification of cannabis as a Schedule I controlled substance under the CSA, banks and other financial institutions which service the cannabis industry are at risk of violating certain financial laws, including anti-money laundering statutes;
  • S. Federal trademark and patent protection may not be available for the intellectual property of the Company due to the current classification of cannabis as a Schedule I controlled substance;
  • the Company’s contracts may not be legally enforceable in the United States;
  • the Company is subject to uncertainty regarding Canadian and U.S. legal and regulatory status and changes.
%d bloggers like this: